Eurocor

Name

Eurocor

Legal name

Eurocor Tech GmbH

Website

https://eurocor.de

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Interventional Cardiovascular Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

akta.pro secondary industry

Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)

Keywords

• Drug-eluting balloons
• Drug-eluting stents
• Vascular intervention devices
• Cardiovascular medical devices
• Peripheral artery treatment

Headquarters

HQ city

Bonn

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales: Eurocor generates revenue through the sale of interventional cardiovascular and peripheral devices including drug-eluting balloons (DIOR®, FREEWAY™), drug-eluting stents (Eurolimus™), and catheter systems. Products are distributed through a network of >150 partners across >60 markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Eurocor develops and manufactures interventional medical devices for minimally invasive cardiovascular and peripheral vascular treatment. Its core product range comprises drug-coated balloon (DCB) catheters and drug-eluting stent (DES) systems, anchored by the DIOR® coronary DEB, the Eurolimus™ sirolimus-eluting coronary stent, and the FREEWAY™ family of peripheral paclitaxel-eluting PTA balloon dilatation catheters (035, 014, and AV Shunt variants). Products are CE-marked, manufactured in Germany under ISO 13485:2016, and sold to hospitals and interventional specialists worldwide.

Product overview

Eurocor Tech GmbH develops and manufactures a comprehensive portfolio of interventional medical devices for cardiovascular and peripheral vascular disease treatment. The product range centers on drug-coated balloon (DCB) and drug-eluting stent (DES) technologies, including the DIOR coronary drug-eluting balloon, the Eurolimus sirolimus-eluting coronary stent system, and the FREEWAY family of peripheral drug-coated balloons available in multiple configurations (FREEWAY 035, FREEWAY 014, and FREEWAY AV Shunt). These products enable percutaneous treatment of coronary artery disease, peripheral artery disease, and AV fistula maintenance through localized drug delivery during angioplasty procedures.

Differentiator

Problem solved

Functional benefit

Brands

• DIOR®: Drug-eluting balloon catheter for cardiovascular interventions
• Eurolimus™
• FREEWAY™

Products and services

• DIOR® Drug-eluting balloon (DEB) catheter for cardiovascular and coronary artery disease treatment, using proprietary paclitaxel-shellac amorphous bioshell coating for localized drug delivery without permanent implant placement. The world's first commercially launched coronary DEB.
• Eurolimus™ Sirolimus-eluting coronary stent system featuring a durable stent platform with biodegradable PLGA 85/15 polymer coating for controlled sirolimus release in treatment of coronary artery disease. CE-marked in 2021.
• FREEWAY™ 035 Paclitaxel-eluting PTA (percutaneous transluminal angioplasty) balloon dilatation catheter for peripheral artery disease treatment, available in extended lengths up to 230 mm for longer lesion coverage.
• FREEWAY™ 014 Paclitaxel-eluting PTA balloon dilatation catheter designed for peripheral vascular interventions with an optimized crossing profile for below-the-knee and other peripheral applications.
• FREEWAY™ AV Shunt Specialized paclitaxel-eluting PTA balloon dilatation catheter designed for maintenance of arteriovenous (AV) fistulas in hemodialysis patients, reducing re-intervention frequency while maintaining patency.

Quantifiable outcome

• 5-year freedom from clinically-driven target lesion revascularization: 85.3% for FREEWAY™ DEB vs 72.7% for PTA (p=0.032)
• +5 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Healthcare Providers and PhysicianscoreStrategic or Co-development PartnerEurocor maintains constant exchange with healthcare providers to understand and deliver on market needs. The company collaborates with physicians for clinical research, product development feedback, and scientific presentations at congresses.
• Distribution PartnerscoreChannel Partner/ Reseller/ DistributorEurocor's distributors are described as equal partners. The company supports partners with tools to evolve further, and exchange of information between Eurocor and partners forms the bedrock of their relationship for unlocking market potential.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• iVascular SLU: iVascular is a Spanish medical device company offering drug-coated balloons (Luminor) for peripheral vascular disease, competing directly with Eurocor's FREEWAY DEBs. Comparable as a European DCB specialist targeting similar indications.
• Concept Medical Inc. Concept Medical is a developer of sirolimus-coated balloons (MagicTouch) directly competing with Eurocor's paclitaxel-based DEB technology in coronary and peripheral indications. Comparable as a focused DCB specialist targeting the same indications.
• Cardionovum GmbH: Cardionovum is a privately-held German company developing paclitaxel-coated balloons (RESTORE) for peripheral and AV-access interventions, overlapping Eurocor's FREEWAY product family. Comparable as a small DCB specialist with similar German/European roots.
• Biotronik SE & Co. KG: Biotronik is a privately-held German cardiovascular device company offering drug-eluting stents (Orsiro) and peripheral balloons, making it the closest geographic and product-line peer to Eurocor. Comparable as a mid-sized specialist DCB/DES competitor with overlapping indication coverage.

Broad incumbents

• Boston Scientific Corporation: Boston Scientific is a global leader in interventional cardiology and peripheral vascular, with the Eluvia and Ranger paclitaxel-eluting stents/balloons directly competing against Eurocor's FREEWAY peripheral DEB. Overlapping product categories, customer base, and indication breadth make it a key broad incumbent benchmark.
• Terumo Corporation: Terumo's interventional systems division produces drug-coated balloons and DES for cardiovascular and peripheral applications, serving the same hospital customer base as Eurocor. Comparable as a broad incumbent with multi-product DCB/DES portfolios.
• Medtronic plc: Medtronic markets the IN.PACT Admiral and IN.PACT 018 paclitaxel-coated balloons for femoropopliteal disease and a broad DES portfolio, making it one of Eurocor's largest DCB competitors in peripheral intervention. Comparable as an incumbent with overlapping indication coverage and physician relationships.
• Abbott Laboratories: Abbott's vascular division markets the Xience DES family and Esprit bioresorbable scaffold, directly competing with Eurocor's Eurolimus sirolimus-eluting stent. Comparable as a broad incumbent with global sales scale Eurocor lacks.
• B. Braun Melsungen AG: B. Braun is a major European medical device and pharmaceutical company with an interventional vascular portfolio including drug-coated balloons (e.g., SeQuent Please) that directly overlaps Eurocor's coronary DEB franchise. Comparable as a broad incumbent selling DCBs/DES into the same hospital channels, with a much larger global footprint.

Emerging players

• Surmodics, Inc. Surmodics developed drug-coated balloon technology (acquired by Abbott) and continues to pursue next-generation DCB coatings, intersecting with Eurocor's proprietary amorphous bioshell coating approach. Comparable as an enabling/coating-technology peer in the DCB value chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Eurocor.Germany
• LinkedInlinkedin.com/company/eurocor
• Instagraminstagram.com/eurocortechgmbh
• Xx.com/eurocor_germany

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eurocor